This informative blog includes:
- A brief overview of guidelines related to E2b.
- Visual representations illustrating the revisions of different E2b versions for easy comprehension.
Table of Contents:
- Introduction
- Guidelines: Their Origin and Development
- Evolution of E2B
- E2B(R2) Revision
- E2B(R3) Revision: Advancements in Safety Transmission
- Freebie for Newbie
- Key Takeaways
- Thoughts
- References
- FAQ
Introduction
This blog is a need of explaining the crucial differences between various E2B revisions. At current stage we are in to the E2B(R3) version.
So this blog explains in details with the differences, variations in revision and what are the upgrades for each version and what kind of benefit of these revisions.
Check out our previous edition which explains details about E2B in role and abbreviations.
Freebie: While perusing this blog, we also provide a complimentary checklist to enhance your ICSR case processing. Feel free to access it while navigating through the content.
Guidelines: Their Origin and Development
The ICH E2B guidelines, part of the “E” category spanning from E2 to E2F, specifically address “Efficacy.” These guidelines define standards related to the design, safety, and reporting of clinical trials and innovative biotech medicines.
π’ Click here to explore more in details and nuances and categories of ICH Guildeines.
Among these guidelines, there are 21 specific ones, including the well-known “Good Clinical Practice.”
E2B(R3), E2B(R2), and E2B specifically detail the transmission of Individual Case Safety Reports (ICSR) in a document titled βClinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports.β
“E2B serves as a submission gateway, but it might not be what you think. There are numerous misconceptions surrounding the E2B gateway. Let’s address and debunk them one by one”.
Evolution of E2B
E2B(R3) and E2B(R2) essentially build upon the foundations laid by E2B but in a more sophisticated manner. So E2B developed to E2B(R2) and now we are in the phase of E2B(R3) submission format.
E2B started the shift from manual handwritten submissions to electronic transmissions.
It outlines the necessary data elements for ICSR submissions, irrespective of the source or destination. Now, we’re advancing to E2B(R3) submission format, a progressive step in this evolution.
E2B(R2) Revision
E2B(R2) signifies the second revision, denoted by the character “R.” It adopted from the original E2B format in February 2001.
In this revision, new data elements were introduced, including Investigational Medicinal Product (IMP) reports. This addition enables enhanced tracking of investigational drugs, a crucial advancement in pharmacovigilance.
E2B(R3) Revision: Advancements in Safety Transmission
E2B(R3) represents the third revision of the E2B format in safety transmission, adopted in 2005. This format aligned with the international HL7 standard, ensuring global compatibility.
Compared to its predecessors, E2B(R3) offers significant improvements. It simplifies processes, enhances data analysis, and refines signal detection techniques.
Notably, it integrates with the Identification of Medicinal Products (IDMP) standards, enhancing cross-referencing and product identification using the HL7 protocol.
One key aspect of E2B(R3) is its case sensitivity, a meticulous detail ensuring accurate data processing. These advancements underscore its pivotal role in the realm of pharmacovigilance under ICH guidelines.
Download our freebie
Version: 1.0
For beginners seeking to enhance their processes with high-quality standards, feel free to download our ICSR Quality Checklist. It’s designed to support your journey and elevate your approach. Get your copy now!
Key Takeaways:
E2B falls under the ‘E‘ category, defining efficacy.
Transitioned from E2B to E2B(R2) in February 2001.
Moved to E2B(R3) in 2005.
E2B(R3) is the third major revision; the term ‘R3‘ indicates revision number 3. Claims of it being the 4th revision are false.
The revisions are from E2B to E2B(R2) and then to E2B(R3).
In ICH E2B(R3) ICSR messages, case-sensitive codes are used.
Authorities accept all formats for submissions; none are excluded.
All three E2B versions focus solely on ICSR management transmission.
All three E2B revisions serve the same purpose: electronic submissions.
Closing thoughts
So by the recent update every member of ICH committee are migrating correlated with the recent format guidelines, so they need to upgrade it by them based on the regulation and conventions.
The FDA, EMA, and Japanβs Ministry of Health, Labour and Welfare (MHLW) have all confirmed they will adopt E2B(R3) as their standard submission format.
All companies that currently report safety data to regulatory agencies or partners using E2B will require to adopt the new E2B(R3) format.
Is there any additional information I may have overlooked? Please feel free to share any details in the comments below.
“Thank you for reading”.
Leave a Reply